Read for 1 minute
The government said on Wednesday that New Zealand’s drug regulator Metsoff had approved the emergency use of the Covit-19 vaccine, developed by US laboratory Pfizer in collaboration with Germany’s Bioendech. / Photo taken on February 1, 2021 / REUTERS / Mike Blake
WELLINGTON (Reuters) – New Zealand drug regulator Metsoff on Wednesday approved the emergency use of the Kovit-19 vaccine, developed by US laboratory Pfizer in collaboration with Germany’s Bioendech.
Prime Minister Jacinta Artern said in a statement that this was a “positive step” in the fight against the epidemic. “We can now begin preparations for the first phase of our vaccination campaign.”
Officials said vaccines should be given by the end of the first quarter. Before the entire population is vaccinated in the second half of the year, people considered to be at high risk will receive the first dose.
(Praveen Menon; French version by Jean Tersian)